| General Information | |
|---|---|
| ZINC ID | ZINC000040881189 |
| Molecular Weight (Da) | 488 |
| SMILES | O=C(NC1CCCCCC1)C(=O)N1CCN([C@@H](c2ccc(Cl)cc2)c2ccccc2Cl)CC1 |
| Molecular Formula | C26Cl2N3O2 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 132.943 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 33 |
| LogP | 5.73 |
| Activity (Ki) in nM | 229.087 |
| Polar Surface Area (PSA) | 52.65 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | + |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.12167751 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 12 |
| Fraction csp3 | 0.46 |
| Ilogp | 4.51 |
| Xlogp3 | 6.04 |
| Wlogp | 3.98 |
| Mlogp | 3.78 |
| Silicos-it log p | 4.83 |
| Consensus log p | 4.63 |
| Esol log s | -6.48 |
| Esol solubility (mg/ml) | 0.000161 |
| Esol solubility (mol/l) | 0.00000033 |
| Esol class | Poorly sol |
| Ali log s | -6.92 |
| Ali solubility (mg/ml) | 0.0000581 |
| Ali solubility (mol/l) | 0.00000011 |
| Ali class | Poorly sol |
| Silicos-it logsw | -7.47 |
| Silicos-it solubility (mg/ml) | 0.0000164 |
| Silicos-it solubility (mol/l) | 3.35E-08 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.99 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 1 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.57 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.362 |
| Logd | 4.37 |
| Logp | 5.262 |
| F (20%) | 0.007 |
| F (30%) | 0.007 |
| Mdck | - |
| Ppb | 97.08% |
| Vdss | 1.939 |
| Fu | 1.07% |
| Cyp1a2-inh | 0.152 |
| Cyp1a2-sub | 0.863 |
| Cyp2c19-inh | 0.891 |
| Cyp2c19-sub | 0.798 |
| Cl | 3.676 |
| T12 | 0.012 |
| H-ht | 0.963 |
| Dili | 0.589 |
| Roa | 0.524 |
| Fdamdd | 0.711 |
| Skinsen | 0.069 |
| Ec | 0.003 |
| Ei | 0.008 |
| Respiratory | 0.191 |
| Bcf | 0.939 |
| Igc50 | 4.717 |
| Lc50 | 5.845 |
| Lc50dm | 4.012 |
| Nr-ar | 0.061 |
| Nr-ar-lbd | 0.004 |
| Nr-ahr | 0.085 |
| Nr-aromatase | 0.789 |
| Nr-er | 0.282 |
| Nr-er-lbd | 0.016 |
| Nr-ppar-gamma | 0.009 |
| Sr-are | 0.544 |
| Sr-atad5 | 0.005 |
| Sr-hse | 0.162 |
| Sr-mmp | 0.555 |
| Sr-p53 | 0.765 |
| Vol | 483.927 |
| Dense | 1.007 |
| Flex | 0.259 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.483 |
| Synth | 2.751 |
| Fsp3 | 0.462 |
| Mce-18 | 78.737 |
| Natural product-likeness | -1.396 |
| Alarm nmr | 0 |
| Bms | 1 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |